clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Arthritis D001168 41 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Psoriasis D011565 47 associated lipids
Parkinson Disease D010300 53 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Pain D010146 64 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Colitis D003092 69 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Cosme A et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. 2013 Clin. Microbiol. Infect. pmid:22512623
Gui J et al. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing]. 2013 Zhonghua Jie He He Hu Xi Za Zhi pmid:24252731
AvÅŸar E et al. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients. 2013 Turk J Gastroenterol pmid:24254262
Smiley R et al. Comparative proteomics analysis of sarcosine insoluble outer membrane proteins from clarithromycin resistant and sensitive strains of Helicobacter pylori. 2013 J. Microbiol. pmid:24173641
Ma Y et al. Characteristics and evaluation of an injectable clarithromycin lipid-based complex in vitro and in vivo. 2013 Drug Deliv pmid:24032596
Patel AM et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. 2013 Ann. Intern. Med. pmid:23778904
Boyanova L et al. Characterization of oral Helicobacter pylori strain by 4 methods. 2013 Diagn. Microbiol. Infect. Dis. pmid:24075629
Morakul B et al. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. 2013 Int J Pharm pmid:24076396
Siamas K and Khachemoune A Mycobacteria infection in an immunocompetent patient with no risk factors: evaluation and management of non-healing majocchi granuloma-type nodule. 2013 Dermatol. Online J. pmid:24021439
Xu Y et al. Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. 2013 Eur J Med Chem pmid:24021890
Ranganathan D et al. Mycobacterium fortuitum peritonitis in a patient receiving continuous ambulatory peritoneal dialysis. 2013 Saudi J Kidney Dis Transpl pmid:24029271
Krashias G et al. Prevalence of Helicobacter pylori cagA and vacA genes in Cypriot patients. 2013 J Infect Dev Ctries pmid:24042099
Lally L and Mannion L The potential for antimicrobials to adversely affect mental state. 2013 BMJ Case Rep pmid:23833088
Nguyen L and Taylor-Gjevre RM An emerging role for clarithromycin in adult-onset still disease? 2013 J Clin Rheumatol pmid:24048102
Murai A et al. Mastitis caused by Mycobacterium kansasii infection in a dog. 2013 Vet Clin Pathol pmid:23808608
Trespalacios AA et al. Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia. 2013 J. Microbiol. pmid:23990295
Berghaus LJ et al. Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. 2013 Vet. Microbiol. pmid:23915992
Saviola G et al. Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study. 2013 Rheumatol. Int. pmid:23864141
Pedersen JM et al. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). 2013 Toxicol. Sci. pmid:24014644
[Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial]. 2013 Jpn J Antibiot pmid:24930240
Guo L et al. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. 2013 Toxicol. Sci. pmid:24052561
Khamraev AA et al. [State of mucosal barrier of the stomach after Helicobacter pylori eradication and ulcer healing in patients with duodenal ulcer disease]. 2013 Eksp Klin Gastroenterol pmid:24933985
Nykula TD and Furleta VV [Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis]. 2013 Lik. Sprava pmid:25095689
Avci O et al. A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. 2013 J Dermatolog Treat pmid:21923567
Sasaki H et al. Ten-year trend of the cumulative Helicobacter pylori eradication rate for the 'Japanese eradication strategy'. 2013 Digestion pmid:24356705
Yuan Y et al. Optimum duration of regimens for Helicobacter pylori eradication. 2013 Cochrane Database Syst Rev pmid:24338763
Amin M et al. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. 2013 Molecules pmid:23434867
Ogata SK et al. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. 2013 J. Pediatr. Gastroenterol. Nutr. pmid:23403439
Morgan DR et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. 2013 JAMA pmid:23403682
Naserpour Farivar T et al. Prevalence of clarithromycin-resistant Helicobacter pylori in patients with chronic tonsillitis by allele-specific Scorpion real-time polymerase chain reaction assay. 2013 Laryngoscope pmid:23404672
Koh WJ et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. 2013 Antimicrob. Agents Chemother. pmid:23478956
Mikamo H et al. [Infection and host reaction]. 2013 Jpn J Antibiot pmid:24649796
Komatsu S et al. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. 2013 Biochem. Biophys. Res. Commun. pmid:23792097
Zhen-Hua Z et al. Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant Helicobacter pylori strains from East China. 2013 Turk J Gastroenterol pmid:23794337
Evdokimova AG et al. [New approaches to therapy of Helicobacterpylori infection (by the materials of the Maastricht Consensus-IV, Florence, 2010)]. 2013 Antibiot. Khimioter. pmid:24640139
Onal IK et al. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. 2013 Clin Res Hepatol Gastroenterol pmid:23796974
de Zeeuw J et al. Serum levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection. 2013 Am. J. Trop. Med. Hyg. pmid:23836576
Janković B et al. Consolidation trend design based on Young's modulus of clarithromycin single crystals. 2013 Int J Pharm pmid:23872226
Shinahara W et al. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. 2013 PLoS ONE pmid:23875018
Friedman ND et al. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. 2013 PLoS Negl Trop Dis pmid:23875050
Suzuki RB et al. Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. 2013 BMC Gastroenterol pmid:24305035
Yano K et al. Clinical outcome of the chronic flexor tenosynovitis in the hand caused by non-tuberculous mycobacterium treated by extensive tenosynovectomy and drugs. 2013 J Plast Surg Hand Surg pmid:23875916
Venerito M et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. 2013 Digestion pmid:23880479
Lee G et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. 2013 Ann Am Thorac Soc pmid:23952847
Bolhuis MS et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. 2013 Antimicrob. Agents Chemother. pmid:23689722
Seddik H et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. 2013 Eur. J. Clin. Pharmacol. pmid:23695545
Ohe M and Hashino S Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide. 2013 Korean J. Intern. Med. pmid:23682236
Dib J et al. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. 2013 Arab J Gastroenterol pmid:24206741
Sadeghifard N et al. Survey in Iran of clarithromycin resistance in Helicobacter pylori isolates by PCR-RFLP. 2013 Southeast Asian J. Trop. Med. Public Health pmid:23682442
Serelis J et al. Granulomatous infection of the hand and wrist due to Azospirillum spp. 2013 Diagn. Microbiol. Infect. Dis. pmid:23685031
Cerqueira L et al. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. 2013 J. Clin. Microbiol. pmid:23596234
Gibbins NE et al. Time to reconsider guidelines on clarithromycin in chronic rhinosinusitis? 2013 BMJ pmid:23635541
Pilcer G et al. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. 2013 Int J Pharm pmid:23643509
Rimbara E et al. Helicobacter cinaedi and Helicobacter fennelliae transmission in a hospital from 2008 to 2012. 2013 J. Clin. Microbiol. pmid:23658263
Bismuth + metronidazole + tetracycline. Why risk adding bismuth? 2013 Prescrire Int pmid:23662315
Zhuo FL et al. Clinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility. 2013 Chin. Med. J. pmid:23673103
Seck A et al. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. 2013 Ann. Clin. Microbiol. Antimicrob. pmid:23298145
Rossi A et al. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. 2013 Blood pmid:23299315
Togami K et al. Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro. 2013 Biol. Pharm. Bull. pmid:23995662
James GD et al. Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. 2013 Prim Care Respir J pmid:23839240
Dumpis U et al. Assessment of antibiotic prescribing in Latvian general practitioners. 2013 BMC Fam Pract pmid:23311389
Huang CW et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. 2013 Int. J. Antimicrob. Agents pmid:23312605
Liu X et al. Clarithromycin-loaded liposomes offering high drug loading and less irritation. 2013 Int J Pharm pmid:23337631
Shinde DD et al. Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. 2013 J Clin Pharmacol pmid:23381968
Singh RP et al. Antimicrobial prophylaxis in open reduction and internal fixation of compound mandibular fractures: a collaborative regional audit of outcome. 2013 Br J Oral Maxillofac Surg pmid:23369782
Prasertpetmanee S et al. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. 2013 Helicobacter pmid:23356886
Nakamura Y et al. Optimal duration of macrolide treatment for chronic sinusitis after endoscopic sinus surgery. 2013 Auris Nasus Larynx pmid:23107100
Sarkeshikian SS et al. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. 2013 Turk J Gastroenterol pmid:23794338
Jouneau S et al. Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. 2013 Respiration pmid:23095475
Higashida A et al. Effectiveness of esomeprazole-based triple therapy of H. pylori in young patients in Japan. 2013 Scand. J. Gastroenterol. pmid:23016956
Kim MS et al. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. 2013 Helicobacter pmid:23066652
Xiong LJ et al. Detection of clarithromycin-resistant Helicobacter pylori by stool PCR in children: a comprehensive review of literature. 2013 Helicobacter pmid:23067446
Kupcinskas L et al. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. 2013 APMIS pmid:23078193
Wu Y et al. Overexpression of YKL-40 predicts plaque instability in carotid atherosclerosis with CagA-positive Helicobacter pylori infection. 2013 PLoS ONE pmid:23573226
Koh WJ et al. Reply: drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions. 2013 Am. J. Respir. Crit. Care Med. pmid:23577353
Schmitt BH et al. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. 2013 Mod. Pathol. pmid:23579617
Lai J et al. Epithelioid histiocytic infiltrate caused by Mycobacterium scrofulaceum infection: a potential mimic of various neoplastic entities. 2013 Am J Dermatopathol pmid:22935892
Boyanova L et al. Living in Sofia is associated with a risk for antibiotic resistance in Helicobacter pylori: a Bulgarian study. 2013 Folia Microbiol. (Praha) pmid:23580173
Bradbeer L et al. Childhood headache and H. pylori--a possible association. 2013 Aust Fam Physician pmid:23529524
Yula E et al. Detection of primary clarithromycin resistance of Helicobacter pylori and association between cagA (+) status and clinical outcome. 2013 Folia Microbiol. (Praha) pmid:22956464
Zhou L et al. Cutaneous Mycobacterium intracellulare infection in an immuno-competent person. 2013 Acta Derm. Venereol. pmid:23532357
Tsuji D et al. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. 2013 Chemotherapy pmid:25011542
Marin AC et al. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). 2013 Expert Opin Pharmacother pmid:23537368
Gokmen T et al. Clarithromycin treatment in preterm infants: a pilot study for prevention of feeding intolerance. 2013 J. Matern. Fetal. Neonatal. Med. pmid:23570248
Metzler K et al. Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. 2013 J. Antimicrob. Chemother. pmid:23169894
Semino-Mora C et al. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution. 2013 Clin. Cancer Res. pmid:23743566
Zullo A et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. 2013 Clin Res Hepatol Gastroenterol pmid:23747131
Markert C et al. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. 2013 Eur. J. Clin. Pharmacol. pmid:23748747
Nishizawa T et al. Delay of second-line eradication therapy for Helicobacter pylori can increase eradication failure. 2013 J. Gastroenterol. Hepatol. pmid:23701705
Lands LC and Stanojevic S Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. 2013 Cochrane Database Syst Rev pmid:23765216
Kwon HJ et al. Life-threatening scrub typhus with hemophagocytosis and acute respiratory distress syndrome in an infant. 2013 J. Trop. Pediatr. pmid:22735791
Liu MK et al. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens. 2013 Kaohsiung J. Med. Sci. pmid:23768702
Li XM et al. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials. 2013 Chin. Med. J. pmid:23769580
Asaoka D et al. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. 2013 Helicobacter pmid:23773231
Al-Haj A et al. Method development, validation and bioequivalence of varenicline in human plasma by liquid chromatography tandem mass spectrometry. 2013 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:23774248
Quinney SK et al. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. 2013 Eur. J. Clin. Pharmacol. pmid:22777148
Kim T et al. [Clarithromycin-resistant Helicobacter pylori associated with 23S rRNA point mutations in Jeju Island]. 2013 Korean J Gastroenterol pmid:23756666
Georgopoulos SD et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. 2013 Helicobacter pmid:23714140
Koh WJ et al. Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. 2013 Antimicrob. Agents Chemother. pmid:23183432
Cerqueira RM et al. Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery. 2013 Obes Surg pmid:23054570